MicroTech Medical (Hangzhou) Co

MicroTech Medical (Hangzhou) Co Current Liabilities

The Current Liabilities of MicroTech Medical (Hangzhou) Co (2235.HK) as of Oct 26, 2026 is 279.52 M CNY. In the previous year, Current Liabilities was 222.17 M CNY — a change of 25.81% (higher).

Current Liabilities

279.52 MCNY

YoY

25.81%

Last updated:

Current Liabilities of MicroTech Medical (Hangzhou) Co is 2025 279.52 M CNY. Current Liabilities of MicroTech Medical (Hangzhou) Co was 2024 222.17 M CNY. It decreases by 25.81% higher compared to the previous year.

The MicroTech Medical (Hangzhou) Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
63.11 M CNY
Jan 1, 2020
66.13 M CNY
Jan 1, 2021
114.59 M CNY
Jan 1, 2022
133.08 M CNY
Jan 1, 2023
137.41 M CNY
Jan 1, 2024
222.17 M CNY
Jan 1, 2025
279.52 M CNY
The MicroTech Medical (Hangzhou) Co Current Liabilities history
YEARCurrent LiabilitiesYoY
279.52 MCNY+25.81%
222.17 MCNY+61.69%
137.41 MCNY+3.25%
133.08 MCNY+16.13%
114.59 MCNY+73.29%
66.13 MCNY+4.79%
63.11 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroTech Medical (Hangzhou) Co Stock analysis

What does MicroTech Medical (Hangzhou) Co do? MicroTech Medical (Hangzhou) Co., Ltd. generates revenue through the sale of diabetes management medical devices and consumables, including the Equil applicator insulin pump system, blood glucose monitoring systems, and the AiDEX G7 continuous blood glucose monitoring system. These products are commercialized for overseas markets such as the United States and the European Union, targeting healthcare providers and patients seeking advanced diabetes care solutions. The company's R&D efforts focus on developing products like the artificial pancreas, which remains in the research phase but is expected to contribute to future revenue streams. The firm's primary customers are healthcare institutions and end-users in international markets, with a strong emphasis on the United States and European Union regions. By leveraging its established product portfolio, MicroTech Medical capitalizes on the growing demand for innovative diabetes management solutions, ensuring consistent revenue from both existing and emerging product lines. The company's IPO in 2021 provided additional capital to support further development and market expansion. MicroTech Medical (Hangzhou) Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroTech Medical (Hangzhou) Co stock

Current Liabilities of MicroTech Medical (Hangzhou) Co is 279.52 M CNY in 2025.

Current Liabilities of MicroTech Medical (Hangzhou) Co changed from 222.17 M CNY to 279.52 M CNY, representing a 25.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities MicroTech Medical (Hangzhou) Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's MicroTech Medical (Hangzhou) Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — MicroTech Medical (Hangzhou) Co

All Key Metrics — MicroTech Medical (Hangzhou) Co